Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 218 publications
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 31, 2026
Combination AURKA and WEE1 inhibition exhibits efficacy in EGFR or pan-ERBB inhibitor resistant head and neck squamous cell carcinoma.
Journal: Cancer research communications
Published: May 21, 2026
Functional impact of transoral surgery and risk-based adjuvant therapy in human papillomavirus-associated oropharyngeal cancer: swallowing outcomes from ECOG-ACRIN E3311.
Journal: JCO oncology advances
Published: April 02, 2026
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.
Journal: Future oncology (London, England)
Published: January 30, 2026
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 23, 2025
Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma.
Journal: Molecular cancer therapeutics
Published: December 02, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Journal: Future oncology (London, England)
Published: October 15, 2025
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).
Journal: Cancer
Published: September 05, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 03, 2025
NN-01-195, a novel conjugate of HSP90 and AURKA inhibitors, effectively targets solid tumors.
Journal: Molecular cancer therapeutics
Published: July 26, 2025
NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors.
Journal: Molecular cancer therapeutics
Published: July 26, 2025
Last Updated: 09/26/2026